NEW YORK — For decades, the shingles vaccine has been recommended to spare older adults from a painful nerve rash. A new study suggests the protection may extend considerably further, into the brain itself.
Researchers analyzing Medicare records of more than half a million adults admitted to skilled nursing facilities across the United States found that those who received Shingrix, the recombinant zoster vaccine, were 24% less likely to develop dementia over a four-year follow-up period than their unvaccinated counterparts. The findings, published in the Annals of Internal Medicine and covered in its report, represent the largest investigation yet into the vaccine’s potential cognitive benefits.
In raw terms, 18.8% of vaccinated patients developed dementia during the study period compared with 24.6% of those who did not receive the vaccine. Researchers estimate one dementia case could be prevented for every 17 adults vaccinated, a ratio that, if confirmed, would rank Shingrix among the most consequential preventive tools available to aging adults.
“Stay tuned,” said Dr. David Reuben, a professor of geriatrics at the David Geffen School of Medicine at UCLA who was not involved in the research. He told patients there is some evidence supporting this finding but that it remains very early.
The study drew on Medicare claims and electronic health records from more than 5,500 skilled nursing facilities nationwide, covering admissions between 2017 and 2022. Only 8,843 of the 509,926 participants had received the vaccine, a proportion the researchers acknowledged as a major limitation, one that makes the findings preliminary rather than definitive.
The mechanism the study’s authors propose centers on the varicella-zoster virus, the pathogen responsible for both chickenpox and, decades later, shingles. When the virus reactivates in older adults, it triggers widespread neuroinflammation, a sustained inflammatory response in the brain that researchers increasingly believe contributes to the accumulation of amyloid and tau, the proteins most closely associated with Alzheimer’s disease. VZV reactivation also increases stroke risk, opening a second pathway to vascular dementia. By suppressing viral reactivation, the vaccine may interrupt both cascades.
That hypothesis aligns with a growing body of evidence. A separate analysis of 1.5 million Medicare beneficiaries found Shingrix linked to a 33% lower risk of dementia, including a 28% reduction in Alzheimer’s disease specifically and a 33% reduction in vascular dementia. An earlier study in Nature Medicine found the recombinant vaccine provided 164 additional days lived without a dementia diagnosis compared with the older live vaccine Zostavax, over a six-year window.
Studies of gene expression patterns tied to inflammatory pathways have increasingly pointed to neuroinflammatory burden as a modifiable target in cognitive aging, a direction the vaccine data reinforces from a different angle.
The new Annals study carries an important caveat: it was funded in part by GlaxoSmithKline, the manufacturer of Shingrix. The researchers stated the company had no control over study design, analysis, or publication decisions. Still, the funding relationship merits scrutiny the authors themselves acknowledge.
The study cannot establish causation. Observational research drawing on existing health records is subject to confounding variables that statistical adjustment cannot fully eliminate. People who receive preventive vaccines may be systematically healthier in other ways, a phenomenon researchers call the healthy-vaccinee effect, which could inflate the apparent benefit.
What the study does not address is whether people outside of skilled nursing facilities would see a comparable benefit, whether the timing of vaccination matters, or whether any cognitive protection, if real, extends beyond four years.
The CDC currently recommends that adults 50 and older receive the two-dose Shingrix series to prevent shingles and its complications, outlining the vaccination protocol in its guidance. The agency has not updated recommendations to include dementia prevention as a formal indication, which typically requires randomized trial evidence.
For physicians managing older patients, the practical implication is narrow but significant: patients already appropriate for Shingrix have an additional reason to complete the series. For patients who have deferred vaccination because shingles seemed a manageable risk, the calculation looks different.
Researchers have increasingly linked viral reactivation to early brain structural changes that accumulate years before any clinical diagnosis, reinforcing the case for preventive intervention at midlife and beyond.
Roughly 7 million Americans are living with Alzheimer’s disease today, a figure CDC projects will rise to nearly 13 million by 2050, in its fact sheet on the disease. At that scale, even a 24% reduction in dementia incidence, if confirmed, would translate into millions of prevented cases.
A randomized trial specifically designed to test whether Shingrix reduces dementia incidence has not been announced. Until that evidence exists, the cognitive benefit of the vaccine remains among the most significant open questions in aging research: not a proven therapy, but not a finding to dismiss.
Related Posts
